Buy DUROLANE® online in Canada at Kinami Health and order a genuine single-injection viscosupplement for professional orthopaedic use. DUROLANE® is a non-animal stabilized hyaluronic acid (NASHA) knee osteoarthritis injection: one 3 mL intra-articular dose that supports joint lubrication and cushioning and helps relieve OA-related knee pain. Kinami Health supplies authentic DUROLANE® to Canadian clinics and licensed medical professionals, with wholesale availability, secure ordering and fast delivery.
Buy DUROLANE® online in Canada at Kinami Health and order a genuine single-injection viscosupplement for professional orthopaedic use. DUROLANE® is a non-animal stabilized hyaluronic acid (NASHA) knee osteoarthritis injection: one 3 mL intra-articular dose that supports joint lubrication and cushioning and helps relieve OA-related knee pain. Kinami Health supplies authentic DUROLANE® to Canadian clinics and licensed medical professionals, with wholesale availability, secure ordering and fast delivery.
Kinami Health makes it simple for Canadian clinics, orthopaedic specialists, sports medicine physicians and licensed healthcare professionals to order DUROLANE® online from a trusted wholesale supplier. Every product is sourced through verified channels for professional use.
When you buy DUROLANE® from Kinami Health, you benefit from:
DUROLANE® is especially relevant for clinics that want a one-visit viscosupplement protocol based on a non-animal hyaluronic acid.
DUROLANE® is built on NASHA (Non-Animal Stabilized Hyaluronic Acid) technology, developed by Q-Med in Sweden – the same stabilization technology behind the RESTYLANE® filler range. The hyaluronic acid is produced by bacterial fermentation, not extracted from animal tissue, and is then stabilized so that it stays in the joint longer than non-stabilized HA.
Each pre-filled syringe contains 60 mg of stabilized sodium hyaluronate in 3 mL (20 mg/mL), administered as a single intra-articular injection by a qualified healthcare professional. Instead of scheduling a course of three to five weekly injections, the full viscosupplement dose is given in one visit.
DUROLANE®, Synvisc One, Monovisc and Orthovisc are all viscosupplements used in the management of knee osteoarthritis, but they differ in HA source, formulation, injection volume and dosing schedule.
Synvisc One is the best-known single-injection viscosupplement in North America and the comparison Canadian clinics make most often. It contains hylan G-F 20, a cross-linked hyaluronan of avian origin, delivered as a 6 mL injection. DUROLANE® is also a single injection, but uses non-animal NASHA hyaluronic acid in a 3 mL volume – a relevant difference when HA source matters to the clinician or the patient. Compare the two on the SYNVISC® brand page.
Monovisc is another single-injection, non-animal option (88 mg of cross-linked HA in 4 mL). The comparison with DUROLANE® mostly comes down to stabilization technology, injection volume, clinician experience and availability. See the MONOVISC® brand page.
Orthovisc is a non-animal, high-molecular-weight HA commonly used as a multi-injection course, so it requires more visits than DUROLANE®. See the ORTHOVISC® brand page.
When choosing between these options, Canadian clinics usually weigh the injection protocol (single vs multi-injection), the HA source (non-animal vs avian-derived), injection volume, patient needs and practitioner preference. The full comparison is in the orthopedic injections category.
In an osteoarthritic knee, the synovial fluid loses part of its viscosity and elasticity, so it lubricates and cushions the joint less effectively. This contributes to pain, stiffness and reduced mobility. DUROLANE® supplements the synovial fluid with stabilized hyaluronic acid, helping restore lubrication and shock absorption inside the joint.
Because NASHA hyaluronic acid is stabilized, it remains in the joint longer than non-stabilized HA, which is what makes a single-injection protocol possible. Clinical data supports DUROLANE® as a single injection that may provide knee osteoarthritis pain relief for up to six months in suitable patients. Results vary with the patient, the severity of osteoarthritis, injection technique and the overall treatment plan.
DUROLANE® should be administered only by qualified healthcare professionals trained in intra-articular injection techniques. In Canada, who may administer intra-articular injections varies by province and professional college, so practitioners should follow the rules that apply in their own jurisdiction.
General administration considerations include:
DUROLANE® is intended for intra-articular use only and must not be used as a dermal filler.
As with any intra-articular injection, side effects can occur. Possible reactions include temporary pain, swelling, warmth or stiffness in the treated joint, and redness or bruising at the injection site. These reactions are usually mild and resolve within a few days.
DUROLANE® should not be used in patients with known hypersensitivity to hyaluronic acid products, or where infection or skin disease is present at or near the injection site. Patients should be assessed by a qualified professional before treatment and advised to report any unusual or persistent symptoms. In Canada, adverse reactions can be reported to Health Canada.
DUROLANE® 3 mL pre-filled syringe – 60 mg of non-animal stabilized sodium hyaluronate (20 mg/mL), a single-injection viscosupplement for knee osteoarthritis, designed for intra-articular administration by qualified healthcare professionals. View the DUROLANE® product page.
